CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in people with cystic fibrosis ("CF") at the 37th Annual North American Cystic Fibrosis Conference, which is being held November 2-4, 2023, in Phoenix, Arizona. The abstract was selected for an oral presentation at the conference.
The Phase 1b/2a data for BX004 will also be available as an e-poster on the virtual congress platform.
Details of the oral presentation are as follows:
Title: A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study evaluating nebulized phage therapy in cystic fibrosis subjects with chronic Pseudomonas aeruginosa pulmonary infection
Session Name: W22-What's New in Clinical Trials in CF?
Session Date and Time: Friday November 3, 2023, 9:30 AM - 11:30 AM MST
Location: 104 AB (West)
The poster will also be made available on the publications section of the BiomX website on November 3, 2023.
About BX004
BiomX is developing BX004, utilizing its proprietary BOLT platform, for the treatment of CF patients with chronic pulmonary infections ...